

**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW



Robert Greene Sterne
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbalia
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
John M. Covert
Robert C. Millonig
Donald J. Featherstone
Timothy J. Shea, Jr.
Michael V. Messenger
Judith U. Kim
Jeffrey T. Helvey
Eldora L. Ellison
Donald R. Banowitz
Peter A. Jackman

Brian J. Del Buono
Mark Fox Evans
Vincent L. Capuano
Elizabeth J. Haanes
Michael D. Specht
Kevin W. McCabe
Glenn J. Perry
Edward W. Yee
Grant E. Reed
Virgil Lee Beaston
Theodore A. Wood
Jason D. Eisenberg
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longworth
Lori A. Gordon

Laura A. Vogel
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schaller
Lei Zhou
W. Blake Coblentz
James J. Pohl
John T. Haran
Mark W. Rygiel
Michael R. Malek
Carla Ji-Eun Kim
Doyle A. Siever
Ulrike Winkler Jenks
Paul A. Calvo
C. Matthew Rozier
Shameek Ghose
Jenny J. Yeh

Randall K. Baldwin
Daniel J. Nevriy
Lori M. Brandes
Jeffrey K. Mills
Mita Mukherjee
Scott M. Woodhouse
Christian A. Camarce
Richard D. Collier III
Bonnie Nannenga-Combs
Alyssa K. Sandrowitz
Ishan P. Weerakoon

Gaurav Asthana
Stephanie L. Elmer
Robert E. Bakin
Salvador M. Bezos
Yasser Mourtada

Of Counsel
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Wrist

Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Peter A. Socarras
Danielle L. Letting
Steven C. Oppenheimer
Aaron S. Lukas

* Admitted only in Maryland
* Admitted only in Virginia
• Practice Limited to
Federal Agencies

May 6, 2008

WRITER'S DIRECT NUMBER:
(202) 772-8822
INTERNET ADDRESS:
SCARROLL@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1632

Attn: Mail Stop Amendment

Re: U.S. Utility Patent Application
Appl. No. 10/561,780; § 371 Date: July 2, 2007
For: **Tissue Modeling In Embryonic Stem (ES) Cell System**
Inventors: KOLOSSOV *et al.*
Our Ref: 2590.0030002/EJH/SAC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
2. Form PTO/SB/08A (1 sheet) listing seven (7) documents (US1-US5 and FP1-FP2);
3. Form PTO/SB/08B (1 sheet) listing ten (10) documents NPL1-NPL10);
4. Copies of cited documents (FP1-FP2 and NPL1-NPL7); and
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.


In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
May 6, 2008
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

A handwritten signature in black ink, reading "Shannon A. Carroll". The signature is fluid and cursive, with the first name "Shannon" being more prominent than the last name "Carroll".

Shannon A. Carroll, Ph.D.
Attorney for Applicants
Registration No. 58,240

SAC/GAL/lam
Enclosures

816067_1.DOC



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KOLOSSOV *et al.*

Appl. No.: 10/561,780 (U.S. Nat'l Phase
of PCT/EP2004/006698;
I.A. fd: June 21, 2004)

§ 371 Date: July 2, 2007

For: **Tissue Modeling In
Embryonic Stem (ES) Cell
System**

Confirmation No.: 5875

Art Unit: 1632

Examiner: NOBLE, Marcia Stephens

Atty. Docket: 2590.0030002/EJH/SAC

**Information Disclosure Statement
Under 37 C.F.R. § 1.97(b)**

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. §1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98.

Copies of documents **FP1**, **FP2**, and **NPL1** to **NPL7** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, documents **US1** to **US5**, cited on the attached IDS Form PTO/SB/08A are not submitted. In addition, copies of documents **NPL8** to **NPL10** are not provided in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

The document **FP1** was cited in a search report by a foreign patent office in a counterpart foreign application. Submission of an English language version of the search report, document **NPL7**, that indicates the degree of relevance found by the foreign office is provided in satisfaction of the requirement for a concise explanation of relevance. 1138 OG 37, 38.

The Examiner's attention is directed to the following co-pending U.S. Patent Applications, which are directed to related technical subject matter:

U.S. Non-Provisional Patent Application No. 10/451,816, U.S. National Phase of PCT/EP01/15337, Int'l Filing Date December 27, 2001, published on May 20, 2004 as U.S. Publication No. 2004/0096432, cited herewith as document **US3**; and

U.S. Non-Provisional Patent Application No. 11/293,932, Filing Date December 5, 2005, published on July 27, 2006 as U.S. Publication No. 2006/0168665, cited herewith as document **US4**; and

U.S. Non-Provisional Patent Application No. 10/594,188, U.S. National Phase of PCT/EP2004/007530, Int'l Filing Date July 8, 2004, published on January 24, 2008 as U.S. Publication No. 2008/0019952, cited herewith as document **US5**; and

U.S. Non-Provisional Patent Application No. 10/594,177, U.S. National Phase of PCT/EP04/07529, Int'l Filing Date July 8, 2004, NOT YET PUBLISHED, cited herewith as document **NPL8**; and

U.S. Non-Provisional Patent Application No. 11/547,871, U.S. National Phase of PCT/EP05/03662, Int'l Filing Date April 7, 2005, NOT YET PUBLISHED, cited herewith as document **NPL9**; and

U.S. Non-Provisional Patent Application No. 11/596,262, U.S. National Phase of PCT/EP05/05087, Int'l Filing Date May 11, 2005, NOT YET PUBLISHED, cited herewith as document **NPL10**.

The identification of these U.S. Patent Applications is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the art cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Shannon A. Carroll, Ph.D.

Attorney for Applicants

Registration No. 58,240

Date: May 6, 2008

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

790851v1